Illumina investment push


Gene sequencing company Illumina has struck a $450 million (£280 million) deal to buy privately owned US firm Verinata Health, which specialises in non-invasive tests for early identification of foetal chromosomal abnormalities.

The deal follows the collapse of Roche’s $5.7 billion hostile bid for Illumina in early 2012 – which the company rejected. It also follows Illumina’s acquisition of BlueGnome, a University of Cambridge spinout that has developed a test for counting chromosomes in a cell.

Illumina will pay $350 million up front, plus up to $100 million in milestone payments.

 


Related Content

Rapid DNA sequencing cleared for the clinic

21 November 2013 Business

news image

Illumina’s ‘next-generation’ MiSeqDx platform gets US approval

Sequencing in the fast lane

25 July 2012 Premium contentFeature

news image

Phillip Broadwith gets up to speed with the latest developments in DNA sequencing technology

Most Commented

Lithium–sulfur batteries ready to go the distance

3 December 2013 Research

news image

Innovative electrodes set to put electric cars in the fast lane with a new design that holds double the energy of ordinary li...

Graphene made in a kitchen blender

22 April 2014 Research

news image

High quality flakes of two-dimensional material exfoliated from graphite points way to bulk production